Article Sidebar

pdf
Date Published: 02/12/2024
Abstract Views: 141
Views pdf: 97
DOI: https://doi.org/10.51298/vmj.v544i3.12058
Issue
Vol. 544 No. 3 (2024)
Section
Các bài báo
How to Cite
Nguyễn, Đình T. V., Nguyễn, T. T. H., Nguyễn, P. D., Nguyễn, C. T. T. T., & Võ , T. H. L. (2024). CASE REPORT MALIGNANT CILIARY BODY MELANOMA – A RARE DISEASE IN CHILDREN AND POSTOPERATIVE IMMUNOTHERAPY. Vietnam Medical Journal, 544(3). https://doi.org/10.51298/vmj.v544i3.12058

CASE REPORT MALIGNANT CILIARY BODY MELANOMA – A RARE DISEASE IN CHILDREN AND POSTOPERATIVE IMMUNOTHERAPY

Đình Thảo Vy Nguyễn, Thị Thanh Hải Nguyễn, Phạm Dũng Nguyễn, Chí Trung Thế Truyền Nguyễn, Thị Hương Lan Võ

Main Article Content

Abstract

Objective: To evaluate treatment effectiveness in Malignant ciliary body melanoma. Methods: A case report of rare stage IIIB Malignant ciliary body melanoma diagnosed in a 13-year-old female patient. She underwent enucleation, followed by immunotherapy, which resulted in a positive outcome. Results: The patient received intravenous Pembrolizumab 90 mg (2mg/kg) every 3 weeks. Treatment evaluation was carried out 6 months after surgery. She also received medications to alleviate other symptoms. Blood tests were indicated to assess liver function, renal function. Eye ultrasound, multi-system ultrasound, vascular Doppler, regional lymph node ultrasound and plain X-ray were also performed to assess recurrence or signs of distant metastasis. The patient was stable and had no sign of recurrence or metastasis. Conclusion: Post-operative immunotherapy for malignant ciliary body melanoma in children helped prevent recurrence and metastasis.

Article Details

Keywords

Ciliary body melanoma, Pembrolizumab.

References

1. M. Costache, O. M. Patrascu, D. Adrian, et al. Ciliary body melanoma - a particularly rare type of ocular tumor. Case report and general considerations. Maedica (Bucur). Sep 2013;8(4):360-4.
2. C. L. Shields, S. Kaliki, M. Furuta, A. Mashayekhi, J. A. Shields. Clinical spectrum and prognosis of uveal melanoma based on age at presentation in 8,033 cases. Retina. Jul 2012;32(7): 1363-72. doi:10.1097/IAE. 0b013e31824d09a8
3. A. D. Singh, M. E. Turell, A. K. Topham. Uveal melanoma: trends in incidence, treatment, and survival. Ophthalmology. Sep 2011;118(9):1881-5. doi:10.1016/j.ophtha.2011.01.040
4. M. Solnik, N. Paduszyńska, A. M. Czarnecka, et al. Imaging of Uveal Melanoma-Current Standard and Methods in Development. Cancers (Basel). Jun 27 2022;14(13)doi:10.3390/ cancers14133147
5. American Joint Committee on Cancer. Classification of Uveal Melanoma (Anatomic Stage). 2018.
6. K. Montazeri, V. Pattanayak, R. J. Sullivan. Tebentafusp in the Treatment of Metastatic Uveal Melanoma: Patient Selection and Special Considerations. Drug Des Devel Ther. 2023;17: 333-339. doi:10.2147/dddt.S368954
7. Rana'a T. Al-Jamal, Nathalie Cassoux, Laurence Desjardins, et al. The Pediatric Choroidal and Ciliary Body Melanoma Study: A Survey by the European Ophthalmic Oncology Group. Ophthalmology. 2016;123(4):898-907. doi:10.1016/j.ophtha.2015.12.024
8. L. A. Raedler. Keytruda (Pembrolizumab): First PD-1 Inhibitor Approved for Previously Treated Unresectable or Metastatic Melanoma. Am Health Drug Benefits. Mar 2015;8(Spec Feature):96-100.
9. Alexander M.M. Eggermont, Michal Kicinski, Christian U. Blank, et al. Five-Year Analysis of Adjuvant Pembrolizumab or Placebo in Stage III Melanoma. NEJM Evidence. 2022;1(11): EVIDoa2200214. doi:doi:10.1056/EVIDoa2200214
10. Ioannis Karydis, Pui Ying Chan, Matthew Wheater, et al. Clinical activity and safety of Pembrolizumab in Ipilimumab pre-treated patients with uveal melanoma. OncoImmunology. 2016/05/03 2016;5(5): e1143997. doi:10.1080/ 2162402X.2016.1143997